MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.surg.2026.110587

Медицинская библиотека · Surgery · 2026

Bone-modifying agents may alter biochemical presentation and operative findings in primary hyperparathyroidism.

Chmiel Abigail C, Giraldo Genesys, Jones Caroline, Freeman Meredith, Yalla Naga M, Gillanders William E, Olson John A, Brown Taylor C

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Primary hyperparathyroidism is closely linked to bone metabolism, leading to increased bone resorption and osteoporosis. Bone-modifying agents are commonly used to mitigate bone loss by altering calcium metabolism; however, their effect on the biochemical and operative presentation of primary hyperparathyroidism has not been well characterized. This study evaluates the association between bone-modifying agent use, biochemical markers, and operative findings among patients with primary hyperparathyroidism.

METHODS

A retrospective review was conducted of patients who underwent parathyroidectomy for primary hyperparathyroidism between 2019 and 2025 at a single tertiary referral center. A history of bone-modifying agent use and bone disease was assessed. Descriptive statistics and univariate analyses were performed to evaluate associations between bone-modifying agent use and the biochemical and operative phenotypes of primary hyperparathyroidism.

RESULTS

A total of 899 patients met inclusion criteria, of whom 187 (20.8%) had a history of bone-modifying agent use. Patients with bone-modifying agent use were more likely to be female (P < .001), White (P < .001), and older on average (70 vs 60 years, P < .001). Mean serum calcium levels (10.5 vs 10.9 mg/dL, P < .001) and mean parathyroid hormone levels (99.5 vs 119.7 pg/mL, P < .001) were lower among bone-modifying agent users. Multigland disease was more frequent in bone-modifying agent users (43% vs 32%, P = .03) as was bilateral neck exploration (54% vs 45%, P = .033).

CONCLUSION

In patients undergoing parathyroidectomy for primary hyperparathyroidism, the use of bone-modifying agents is associated with a distinct biochemical profile and a higher prevalence of multigland disease. A more nuanced understanding of the relationship between bone-modifying agents and the pathophysiology and surgical presentation of primary hyperparathyroidism could inform preoperative planning and guide individualized evaluation strategies in this patient population.

Для цитирования: Chmiel Abigail C, Giraldo Genesys, Jones Caroline, Freeman Meredith, Yalla Naga M, Gillanders William E, Olson John A, Brown Taylor C. Bone-modifying agents may alter biochemical presentation and operative findings in primary hyperparathyroidism.. Surgery. 2026. DOI: 10.1016/j.surg.2026.110587.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.